Clinical Trial

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 28, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-10-04; most recent amendment 2025-11-25.
Trial Details
NCT Number NCT06073574
Lead Sponsor Ionis Pharmaceuticals, Inc.
Collaborators: AstraZeneca
Conditions Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Enrollment 150 participants
Start Date 2021-03-31
Primary Completion 2026-03 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-11-28